Copyright Reports & Markets. All rights reserved.

Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2021

Request for Sample of this report
Buy now

1 PROteolysis Targeting Chimera (PROTAC) Market Overview

  • 1.1 Product Overview and Scope of PROteolysis Targeting Chimera (PROTAC)
  • 1.2 PROteolysis Targeting Chimera (PROTAC) Segment by Type
    • 1.2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 ARV-110
    • 1.2.3 ARV-471
    • 1.2.4 KYM-001
    • 1.2.5 Others
  • 1.3 PROteolysis Targeting Chimera (PROTAC) Segment by Application
    • 1.3.1 PROteolysis Targeting Chimera (PROTAC) Sales Comparison by Application: (2021-2027)
    • 1.3.2 Oncology
    • 1.3.3 Others
  • 1.4 Global PROteolysis Targeting Chimera (PROTAC) Market Size Estimates and Forecasts
    • 1.4.1 Global PROteolysis Targeting Chimera (PROTAC) Revenue 2016-2027
    • 1.4.2 Global PROteolysis Targeting Chimera (PROTAC) Sales 2016-2027
    • 1.4.3 PROteolysis Targeting Chimera (PROTAC) Market Size by Region: 2016 Versus 2021 Versus 2027

2 PROteolysis Targeting Chimera (PROTAC) Market Competition by Manufacturers

  • 2.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global PROteolysis Targeting Chimera (PROTAC) Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers PROteolysis Targeting Chimera (PROTAC) Manufacturing Sites, Area Served, Product Type
  • 2.5 PROteolysis Targeting Chimera (PROTAC) Market Competitive Situation and Trends
    • 2.5.1 PROteolysis Targeting Chimera (PROTAC) Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest PROteolysis Targeting Chimera (PROTAC) Players Market Share by Revenue
    • 2.5.3 Global PROteolysis Targeting Chimera (PROTAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario by Region

  • 3.1 Global PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global PROteolysis Targeting Chimera (PROTAC) Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
    • 3.3.1 North America PROteolysis Targeting Chimera (PROTAC) Sales by Country
    • 3.3.2 North America PROteolysis Targeting Chimera (PROTAC) Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
    • 3.4.1 Europe PROteolysis Targeting Chimera (PROTAC) Sales by Country
    • 3.4.2 Europe PROteolysis Targeting Chimera (PROTAC) Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Region
    • 3.5.1 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Sales by Region
    • 3.5.2 Asia Pacific PROteolysis Targeting Chimera (PROTAC) Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
    • 3.6.1 Latin America PROteolysis Targeting Chimera (PROTAC) Sales by Country
    • 3.6.2 Latin America PROteolysis Targeting Chimera (PROTAC) Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Sales by Country
    • 3.7.2 Middle East and Africa PROteolysis Targeting Chimera (PROTAC) Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Analysis by Type

  • 4.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Type (2016-2021)
  • 4.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Type (2016-2021)
  • 4.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Type (2016-2021)

5 Global PROteolysis Targeting Chimera (PROTAC) Historic Market Analysis by Application

  • 5.1 Global PROteolysis Targeting Chimera (PROTAC) Sales Market Share by Application (2016-2021)
  • 5.2 Global PROteolysis Targeting Chimera (PROTAC) Revenue Market Share by Application (2016-2021)
  • 5.3 Global PROteolysis Targeting Chimera (PROTAC) Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Arvinas
    • 6.1.1 Arvinas Corporation Information
    • 6.1.2 Arvinas Description and Business Overview
    • 6.1.3 Arvinas PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Arvinas Product Portfolio
    • 6.1.5 Arvinas Recent Developments/Updates
  • 6.2 Kymera
    • 6.2.1 Kymera Corporation Information
    • 6.2.2 Kymera Description and Business Overview
    • 6.2.3 Kymera PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Kymera Product Portfolio
    • 6.2.5 Kymera Recent Developments/Updates
  • 6.3 C4 therapeutics
    • 6.3.1 C4 therapeutics Corporation Information
    • 6.3.2 C4 therapeutics Description and Business Overview
    • 6.3.3 C4 therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 C4 therapeutics Product Portfolio
    • 6.3.5 C4 therapeutics Recent Developments/Updates
  • 6.4 Captor therapeutics
    • 6.4.1 Captor therapeutics Corporation Information
    • 6.4.2 Captor therapeutics Description and Business Overview
    • 6.4.3 Captor therapeutics PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Captor therapeutics Product Portfolio
    • 6.4.5 Captor therapeutics Recent Developments/Updates
  • 6.5 Vividion
    • 6.5.1 Vividion Corporation Information
    • 6.5.2 Vividion Description and Business Overview
    • 6.5.3 Vividion PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Vividion Product Portfolio
    • 6.5.5 Vividion Recent Developments/Updates
  • 6.6 Cullgen
    • 6.6.1 Cullgen Corporation Information
    • 6.6.2 Cullgen Description and Business Overview
    • 6.6.3 Cullgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Cullgen Product Portfolio
    • 6.6.5 Cullgen Recent Developments/Updates
  • 6.7 Pfizer
    • 6.6.1 Pfizer Corporation Information
    • 6.6.2 Pfizer Description and Business Overview
    • 6.6.3 Pfizer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Pfizer Product Portfolio
    • 6.7.5 Pfizer Recent Developments/Updates
  • 6.8 Merck
    • 6.8.1 Merck Corporation Information
    • 6.8.2 Merck Description and Business Overview
    • 6.8.3 Merck PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Merck Product Portfolio
    • 6.8.5 Merck Recent Developments/Updates
  • 6.9 Genentech
    • 6.9.1 Genentech Corporation Information
    • 6.9.2 Genentech Description and Business Overview
    • 6.9.3 Genentech PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Genentech Product Portfolio
    • 6.9.5 Genentech Recent Developments/Updates
  • 6.10 AstraZeneca
    • 6.10.1 AstraZeneca Corporation Information
    • 6.10.2 AstraZeneca Description and Business Overview
    • 6.10.3 AstraZeneca PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 AstraZeneca Product Portfolio
    • 6.10.5 AstraZeneca Recent Developments/Updates
  • 6.11 Amgen
    • 6.11.1 Amgen Corporation Information
    • 6.11.2 Amgen PROteolysis Targeting Chimera (PROTAC) Description and Business Overview
    • 6.11.3 Amgen PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Amgen Product Portfolio
    • 6.11.5 Amgen Recent Developments/Updates
  • 6.12 Bayer
    • 6.12.1 Bayer Corporation Information
    • 6.12.2 Bayer PROteolysis Targeting Chimera (PROTAC) Description and Business Overview
    • 6.12.3 Bayer PROteolysis Targeting Chimera (PROTAC) Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Bayer Product Portfolio
    • 6.12.5 Bayer Recent Developments/Updates

7 PROteolysis Targeting Chimera (PROTAC) Manufacturing Cost Analysis

  • 7.1 PROteolysis Targeting Chimera (PROTAC) Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of PROteolysis Targeting Chimera (PROTAC)
  • 7.4 PROteolysis Targeting Chimera (PROTAC) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 PROteolysis Targeting Chimera (PROTAC) Distributors List
  • 8.3 PROteolysis Targeting Chimera (PROTAC) Customers

9 PROteolysis Targeting Chimera (PROTAC) Market Dynamics

  • 9.1 PROteolysis Targeting Chimera (PROTAC) Industry Trends
  • 9.2 PROteolysis Targeting Chimera (PROTAC) Growth Drivers
  • 9.3 PROteolysis Targeting Chimera (PROTAC) Market Challenges
  • 9.4 PROteolysis Targeting Chimera (PROTAC) Market Restraints

10 Global Market Forecast

  • 10.1 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Type (2022-2027)
  • 10.2 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Application (2022-2027)
  • 10.3 PROteolysis Targeting Chimera (PROTAC) Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of PROteolysis Targeting Chimera (PROTAC) by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of PROteolysis Targeting Chimera (PROTAC) by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    ARV-110
    ARV-471
    KYM-001
    Others

    Segment by Application
    Oncology
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Arvinas
    Kymera
    C4 therapeutics
    Captor therapeutics
    Vividion
    Cullgen
    Pfizer
    Merck
    Genentech
    AstraZeneca
    Amgen
    Bayer

    Buy now